1. Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial;Al-Sawaf;Blood,2019
2. Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study;Al-Sawaf;Hematol. Oncol.,2021
3. Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia;Aronson;Ann. Intern. Med.,2016
4. AstraZeneca, 2019. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia - CSR..
5. Ibrutinib versus chlorambucil in patients 65 years and older with treatment-Naive CLL/SLL (RESONATE-2TM): an international randomized phase 3 study;Burger;J. Oncol. Pharm. Pract.,2016